论文标题
对生物技术初创公司的系统分析，该初创公司在2021年上半年公开
A systematic analysis of biotech startups that went public in the first half of 2021
论文作者
论文摘要
生物技术正在以历史悠久的速度进行商业化。在2020年，有74家生物技术初创公司通过首次公开募股（IPO）公开，而60家在2021年的头六个月中进行了IPO流程。但是，与生物技术初创公司有关的特征尚未报道获得最近的IPOS的特征。在这里，我们构建了一个生物技术数据库，该数据库在2021年上半年进行了IPO。通过分析领导力，技术重点，临床试验和融资，我们发现领导力，临床试验和知识产权之间的高级学位是生物技术创业公司的重要因素。数据还表明，大型私人回合可以减少IPO的时间并影响IPO后股票的性能。值得注意的是，这些特征通常在2018 - 2019年在138个生物技术IPO上表现出来，这表明2021个数据不是由COVID驱动的。
Biotechnologies are being commercialized at historic rates. In 2020, 74 biotech startups went public through an Initial Public Offering (IPO), and 60 went through the IPO process in the first six months of 2021. However, the traits associated with biotech startups obtaining recent IPOs have not been reported. Here we build a database of biotechs that underwent an IPO in the first half of 2021. By analyzing leadership, technological focus, clinical trials, and financing, we found that advanced degrees among the leadership, clinical trials, and intellectual property are important factors for biotech startups. The data also suggest that large private rounds can decrease time-to-IPO and affect post-IPO stock performance. Notably, these traits were often exhibited by the 138 biotech IPOs in 2018-2019, suggesting 2021 data were not driven by COVID.
